Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII delta II
- PMID: 1900236
- DOI: 10.1111/j.1432-1033.1991.tb15748.x
Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII delta II
Abstract
Factor VIII delta II is a genetically engineered deletion variant of factor VIII expressed by recombinant Chinese hamster ovary cells, in which a major portion of the central (B) domain and a part of the light chain (Pro771-Asp1666) are missing. After immunoaffinity purification, the kinetics of thrombin cleavage of the novel molecule was analysed by SDS/PAGE, Western blotting and N-terminal amino acid sequencing. Thrombin first cleaves factor VIII delta II at Arg740-Ser741 to generate the 90-kDa heavy chain and an 80-kDa fusion polypeptide consisting of the remaining portion of the B domain and the 73-kDa light chain. The 90-kDa fragment is further cleaved, giving rise to 50-kDa and 40-kDa fragments while the 80-kDa fragment generates a 71/73-kDa doublet. The 71/73-kDa doublet, 50-kDa and 40-kDa fragments were further analysed by N-terminal amino acid sequencing and found to correspond to the predicted amino acid sequences. Our study shows that, in spite of the 900 amino acid deletion present in factor VIII delta II, the essential structural elements required for thrombin activation are conserved.
Similar articles
-
Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.Biochem J. 1991 Jul 1;277 ( Pt 1)(Pt 1):23-31. doi: 10.1042/bj2770023. Biochem J. 1991. PMID: 1906711 Free PMC article.
-
Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.Biochem J. 1995 Nov 15;312 ( Pt 1)(Pt 1):49-55. doi: 10.1042/bj3120049. Biochem J. 1995. PMID: 7492334 Free PMC article.
-
Characterization of a recombinant antihaemophilia-A factor (factor VIII-delta II) by matrix-assisted laser desorption/ionization mass spectrometry.Rapid Commun Mass Spectrom. 1995;9(15):1584-8. doi: 10.1002/rcm.1290091524. Rapid Commun Mass Spectrom. 1995. PMID: 8652881
-
Amino acid residues 721-729 are required for full factor VIII activity.Eur J Biochem. 1995 Dec 15;234(3):773-9. doi: 10.1111/j.1432-1033.1995.773_a.x. Eur J Biochem. 1995. PMID: 8575434
-
Expression and structure-function properties of recombinant factor VIII.Transfus Med Rev. 1992 Oct;6(4):235-46. doi: 10.1016/s0887-7963(92)70174-6. Transfus Med Rev. 1992. PMID: 1421822 Review. No abstract available.
Cited by
-
Blood Clotting Factor VIII: From Evolution to Therapy.Acta Naturae. 2013 Apr;5(2):19-39. Acta Naturae. 2013. PMID: 23819034 Free PMC article.
-
Mammalian Metallothionein-3: New Functional and Structural Insights.Int J Mol Sci. 2017 May 24;18(6):1117. doi: 10.3390/ijms18061117. Int J Mol Sci. 2017. PMID: 28538697 Free PMC article. Review.
-
Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.J Thromb Haemost. 2017 Jan;15(1):110-121. doi: 10.1111/jth.13543. Epub 2016 Nov 25. J Thromb Haemost. 2017. PMID: 27749002 Free PMC article.
-
Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.Mol Ther. 2015 Apr;23(4):617-26. doi: 10.1038/mt.2015.20. Epub 2015 Feb 6. Mol Ther. 2015. PMID: 25655313 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources